[Von Hippel-Lindau disease].
Takahashi
Kentaro
K
Division of Endocrinology/Metabolism, Neurology and Hematology/Oncology, Department of Clinical Molecular Medicine, Kobe University Graduate School of Medicine.
Iida
Keiji
K
Chihara
Kazuo
K
D000310:Adrenal Gland Neoplasms / Q000209:etiology / Q000628:therapy; D002292:Carcinoma, Renal Cell / Q000209:etiology / Q000628:therapy; D016543:Central Nervous System Neoplasms / Q000209:etiology / Q000628:therapy; D003937:Diagnosis, Differential; D018325:Hemangioblastoma / Q000209:etiology / Q000628:therapy; D006391:Hemangioma / Q000209:etiology / Q000628:therapy; D006801:Humans; D007680:Kidney Neoplasms / Q000209:etiology / Q000628:therapy; D009154:Mutation; D010673:Pheochromocytoma / Q000209:etiology / Q000628:therapy; D011379:Prognosis; D019572:Retinal Neoplasms / Q000209:etiology / Q000628:therapy; D051794:Von Hippel-Lindau Tumor Suppressor Protein / Q000235:genetics; D006623:von Hippel-Lindau Disease / Q000150:complications / Q000175:diagnosis / Q000235:genetics / Q000628:therapy
D051794:Von Hippel-Lindau Tumor Suppressor Protein; C497446:VHL protein, human